Monocytes and interstitial macrophages contribute to hypoxic pulmonary hypertension

Rahul Kumar1,2, Kevin Nolan1, Biruk Kassa1

  • 1Department of Medicine, University of California San Francisco, San Francisco, California, USA.

Insights

Hypoxia triggers pulmonary hypertension by activating specific lung macrophages. Blocking this pathway with dexamethasone shows therapeutic potential for this vascular disease.

Area of Science:

  • Pulmonary vascular disease
  • Immunology
  • Macrophage biology

Background:

  • Hypoxia is a leading cause of pulmonary hypertension (PH).
  • Interstitial pulmonary macrophages are implicated in PH pathogenesis.
  • Understanding macrophage roles in hypoxic PH is crucial for developing treatments.

Purpose of the Study:

  • To investigate the role of interstitial macrophages in hypoxia-induced pulmonary hypertension.
  • To identify specific macrophage populations and signaling pathways involved in PH development.
  • To explore potential therapeutic targets for hypoxic PH.

Main Methods:

  • Utilized a hypoxia-exposed mouse model to study pulmonary hypertension.
  • Analyzed macrophage populations, proliferation, and gene expression (CCL2, CCR2, thrombospondin-1).
  • Investigated the effects of blocking monocyte recruitment (CCL2 antibody, CCR2 deficiency) and dexamethasone treatment.
  • Examined human plasma samples from individuals ascending to high altitude.

Main Results:

  • Hypoxia increased resident interstitial macrophages via proliferation and CCL2 expression.
  • Recruited CCR2+ macrophages expressed thrombospondin-1, activating TGF-β and causing vascular disease.
  • Blocking monocyte recruitment or CCR2 deficiency suppressed hypoxic PH.
  • Human plasma showed increased thrombospondin-1 and TGF-β at high altitude, blocked by dexamethasone.
  • Dexamethasone suppressed CCL2 expression and CCR2+ monocyte recruitment in mice.

Conclusions:

  • A pathological crosstalk exists between two distinct interstitial macrophage populations in hypoxic PH.
  • CCL2-mediated monocyte recruitment and CCR2+ macrophage activation are key drivers of vascular disease.
  • Targeting this macrophage-driven pathway, potentially with dexamethasone, offers a therapeutic strategy for hypoxic PH.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
147
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
166
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
869